Avacta Group (AVCT) AGM 2024 summary

Opening remarks and agenda

• Emphasis on a singular focus for novel therapeutics and a revolutionary approach leveraging peptide drug conjugates targeting FAP in the tumor microenvironment.

• Agenda included board and management team updates, financial planning, business update, therapeutic strategy, pipeline evolution, and milestones.

Board and executive committee updates

• Introduction of a reshaped board, including a new non-executive director, Darlene Deptula-Hicks, with global financial expertise.

• Shaun Chilton serves as chairman, Christina Coughlin as CEO since end of April, and other key committee chairs were introduced.

• Executive management team includes Chief Business Officer Simon Bennett, COO Karen Harrison, Head of Cancer Biology David Jones, and Head of Chemistry Francis Wilson.

• Announcement of a new scientific advisory board with key opinion leaders from oncology and cardiology, supporting clinical and pipeline development.

Financial performance review

• Discussion of a challenging global funding environment, with the UK market remaining difficult and the US more supportive for the company's stage.

• Recent rights raise funded both therapeutics and diagnostics; ongoing significant funding requirements for pipeline and clinical trials.

• Focus on bridging the funding gap through non-dilutive capital sources, including realizing value from diagnostics assets and business development strategies.

• Management is engaging with institutional investors and attending global conferences to secure medium and long-term capital.